BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Izurieta P, Breuer T. Interpretation of the switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10 in Belgium. The Lancet Infectious Diseases 2018;18:831-2. [DOI: 10.1016/s1473-3099(18)30410-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Wasserman MD, Sings HL, Wilson MR, Postma MJ, Breton MC, McDade C, Farkouh RA. Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium. Infect Dis Ther 2019;8:1-3. [PMID: 30460606 DOI: 10.1007/s40121-018-0222-1] [Reference Citation Analysis]
2 Quattrone F, Donzelli G, D'Arienzo S, Fornili M, Innocenti F, Forni S, Baglietto L, Tavoschi L, Lopalco PL. Invasive Pneumococcal Disease in Tuscany Region, Italy, 2016-2017: Integrating Multiple Data Sources to Investigate Underreporting. Int J Environ Res Public Health 2020;17:E7581. [PMID: 33086480 DOI: 10.3390/ijerph17207581] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Suwantika AA, Zakiyah N, Kusuma ASW, Abdulah R, Postma MJ. Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia. Vaccines (Basel) 2020;8:E233. [PMID: 32443523 DOI: 10.3390/vaccines8020233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A, Zollo A, Icardi G. Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens 2020;9:E76. [PMID: 31979079 DOI: 10.3390/pathogens9020076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]